Medical Affairs: Strategic Lifecycle Partner
- Decoding country-by-country HTA differences and their impact on launch timelines
- Preparing comparative data packages aligned with EU national requirements
- Strategizing launch sequencing to avoid reimbursement bottlenecks
- The evolving role of Medical Affairs as a strategic partner across the development lifecycle, particularly how earlier involvement can improve trial design, strengthen evidence generation, and ultimately accelerate the path to patients